Mark Wansbrough‐Jones

Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of <i>Mycobacterium ulcerans</i> in Early Lesions of Buruli Ulcer in Humans

Samuel Etuaful, B Carbonnelle, J Grosset et al. · Antimicrobial Agents and Chemotherapy · 2005 · 244 citations

Life Sciences, Dermatology, Microbiology +16

Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy

Nicholas I. Paton, Ruth Goodall, David Dunn et al. · JAMA · 2012 · 156 citations · Full text

Medicine, Immunology, Pharmacology +17

Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of<i>Mycobacterium ulcerans</i>Disease

Fred Stephen Sarfo, Richard Odame Phillips, Kingsley Asiedu et al. · Antimicrobial Agents and Chemotherapy · 2010 · 115 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

Richard Odame Phillips, J. Robert, Kabiru Mohamed Abass et al. · The Lancet · 2020 · 110 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Sensitivity of PCR Targeting the IS <i>2404</i> Insertion Sequence of <i>Mycobacterium ulcerans</i> in an Assay Using Punch Biopsy Specimens for Diagnosis of Buruli Ulcer

Richard Odame Phillips, Catherine Horsfield, Sjoukje Kuijper et al. · Journal of Clinical Microbiology · 2005 · 91 citations · Full text

Life Sciences, Microbiology, Pathology +16